Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 699-703

  Tsirlis, Theodoros D ^a   Kostakis, Alkiviadis ^b   Papastratis, George ^a   Masselou, Kiriaki ^a   Vlachos, Ioannis ^c   Papachristodoulou, Antonios ^b   Nikiteas, Nikolaos I ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

gastric cancer; lymph node metastasis; predictive markers; serum VEGF C VEGF D

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER; VASCULOTROPIN C; VASCULOTROPIN D;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; PARTIAL GASTRECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; TOTAL STOMACH RESECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 78349241703     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21677     Document Type: Article

References (32)

1. Axon A,: Symptoms and diagnosis of gastric cancer at early curable stage. Best Pract Res Clin Gastroenterol 2006; 20: 697-708.
2. Bowrey DJ, Griffin SM, Wayman J,: Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. Surg Endosc 2006; 20: 1725-1728.
3. Talley NJ, Vakil NB, Moayyedi P,: American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-1780.
4. Marrelli D, Pinto E, De Stefano A, et al.: Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001; 181: 16-19.
5. Kochi M, Fujii M, Kanamori N, et al.: Evaluation of serum CEA and CA 19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000; 3: 177-186.
6. Ishigami S, Natsugoe S, Hokita S, et al.: Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001; 32: 41-44.
7. Liakakos T, Roukos DH,: More controversy than ever-Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008; 15: 956-960.
8. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004; CD001964.
9. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
10. Kwee RM, Kwee TC,: Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 2009; 12: 6-22.
11. Kukk E, Lymboussaki A, Taira S, et al.: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829-3837.
12. Achen MG, Jeltsch M, Kukk E, et al.: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-553.
13. He Y, Rajantie I, Pajusola K, et al.: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005; 65: 4739-4746.
14. Yonemura Y, Endo Y, Fujita H, et al.: Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829.
15. Shida A, Fujioka S, Kobayashi K, et al.: Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 2006; 11: 38-43.
16. Kitadai Y, Kodama M, Cho S, et al.: Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 2005; 115: 388-392.
17. Jüttner S, Wissmann C, Jóns T, et al.: Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240.
18. Ichikura T, Tomimatsu S, Ohkura E, et al.: Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001; 78: 132-137.
19. Arigami T, Natsugoe S, Uenosono Y, et al.: Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg Oncol 2009; 99: 148-153.
20. Ishikawa M, Kitayama J, Kazama S, et al.: Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn J Clin Oncol 2003; 33: 21-27.
21. Yonemura Y, Endo Y, Tabata K, et al.: Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol 2005; 10: 318-327.
22. Wang TB, Deng MH, Qiu WS, et al.: Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797; discussion 1797-1798.
23. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, et al.: Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14: 3879-3883.
24. Alabi AA, Suppiah A, Madden LA, et al.: Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int J Colorectal Dis 2009; 24: 269-274.
25. Duff SE, Saunders M, McCredie V, et al.: Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol) 2005; 17: 367-371.
26. Mitsuhashi A, Suzuka K, Yamazawa K, et al.: Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005; 103: 724-730.
27. Hassan H, Vilmann P, Sharma V,: Impact of EUS-guided FNA on management of gastric carcinoma. Gastrointest Endosc 2010; 71: 500-504.
28. Nakagoe T, Sawai T, Tsuji T, et al.: Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res 2002; 22: 451-458. (Pubitemid 34475338)
29. Koyama Y, Kaneko K, Akazawa K, et al.: Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: Association with lymph node metastasis. Clin Breast Cancer 2003; 4: 354-360.
30. Niki T, Iba S, Tokunou M, et al.: Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6: 2431-2439.
31. Tsirlis TD, Papastratis G, Masselou K, et al.: Circulating lymphangiogenic growth factors in gastrointestinal solid tumors; could they be of any clinical significance? World J Gastroenterol 2008; 14: 2691-2701.
32. Ji RC,: Lymph node lymphangiogenesis: A new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol 2009; 24: 377-384.